
    
      This is a single center, randomized, open-label, phase 2 trial to evaluate the
      time-to-improvement in the 7 point ordinal scale following treatment with anti-IL-8 therapy
      (BMS-986253) compared to standard of care in hospitalized patients with COVID-19 respiratory
      disease. Patients will be randomized 2:1 to receive either BMS-986253 or standard of care.
      Patients randomized to treatment with BMS-986253 will receive between 1-3 doses of therapy
      depending on their clinical status. Participants will be assessed daily while in the hospital
      and with then be followed for up to 1 year after discharge.
    
  